VC
Value Add VC
⚡HomePulse⚡Helpful Apps📝Blog🤝Partner
Illustration for: Berry Street Merges With Healthify on GLP-1 Demand
Value Add VC/Pulse/FUNDINGDEEP DIVE

Berry Street Merges With Healthify on GLP-1 Demand

US nutrition startup Berry Street is merging with India's Healthify as GLP-1 drug adoption pushes demand for dietitian services and metabolic coaching.

TC
By the Funding Desk
Edited by Trace Cohen · Early-stage VC & angel · Founder, New York Venture Partners
August 24, 2026
2 min read
ShareXLinkedInEmail

THE RUNDOWN

1

Berry Street is merging with Healthify as GLP-1 trends push demand for nutrition support, [TechCrunch reported](https://techcrunch.com/2026/08/24/us-nutrition-startup-berry-street-merges-with-indias-healthify-as-glp-1-trends-upwards/)

2

GLP-1 drugs create a durable services layer -- patients on them need dietitian oversight to preserve muscle mass and manage side effects

3

A cross-border merger between a US insurance-billing business and an Indian consumer-health platform is an unusual structure with real operational complexity

4

Insurance reimbursement for medical nutrition therapy is the underappreciated part of this model and the part that makes revenue durable

TC

The VC Read · Trace's Take

Trace Cohen

The GLP-1 services layer is one of the few healthcare categories where the payer, the patient and the prescriber all want the same thing, which is rare enough to be worth underwriting. What I'd check in this deal is the share of Berry Street revenue that is in-network commercial versus cash-pay -- reimbursement rates for medical nutrition therapy have been revised before, and a single CPT code change would reset the model.

Funding Rounds →

Analysis

Berry Street, a US startup that connects patients with registered dietitians and bills insurance for the visits, is merging with Healthify, the Indian consumer health and nutrition platform, TechCrunch reported, citing rising GLP-1 adoption as the driver.

Berry Street's business rests on an underused piece of the US benefits system: medical nutrition therapy is a covered benefit under most commercial plans, often with no copay, and almost nobody uses it because finding an in-network dietitian is difficult. Berry Street built the matching and billing infrastructure and grew quickly on that arbitrage. Healthify, founded in 2012 as HealthifyMe by Tushar Vashisht and Sachin Shenoy, took the opposite route -- a consumer subscription app with tens of millions of users in India and a large coaching workforce.

“Berry Street built the matching and billing infrastructure and grew quickly on that arbitrage.”

GLP-1 drugs are the connective logic. Patients on semaglutide and tirzepatide eat substantially less, which raises real risks of muscle loss and nutrient deficiency, and clinical guidance increasingly pairs the prescription with structured nutrition support. That turns dietitian access from a wellness nicety into part of a drug protocol, with a payer willing to fund it.

The category has drawn a wave of venture interest for exactly this reason. Noom pivoted much of its coaching product toward GLP-1 support after its diet-app growth stalled, Ro built out a full prescribing-to-pharmacy pipeline for the drugs themselves, and a long tail of telehealth startups have positioned themselves as the compliance and side-effect-management layer sitting alongside the prescription. Berry Street's differentiation is that it bills insurance rather than charging cash, which is a slower, more operationally demanding business to build but produces revenue that does not depend on a patient's willingness to pay out of pocket every month.

The hard part is the merger itself. Combining a US regulated-billing business with an Indian consumer subscription business means two revenue models, two compliance regimes and two very different cost structures for delivering human coaching. Cross-border health mergers have a poor track record precisely because clinical labor does not port across regulatory borders, and the value here depends on whether Healthify's coaching capacity can legally serve US patients or merely support them.

Related Deep Dives

  • $1.63B Raised, 36% Faster — Health Insurance AI (2026) →
  • AI Tutor Education Startups 2026: Duolingo's $1.2B, Khanm... →
  • Fund I vs Fund II VC Performance: Does the Sophomore Fund... →
ShareXLinkedInEmail

Key Sources

2 sources
SourceTechCrunch
AnalysisValue Add Pulse

Reported by TechCrunch · Analysis by Value Add Pulse.

← Back to Pulse

THE WIRE in your inbox— Tech, startup & VC news with Trace's take. Free, no spam.

Read Next

FUNDING· Aug 24, 2026

General Intuition Hits $6B Valuation on Robotics Push

Illustration for: General Intuition Hits $6B Valuation on Robotics Push
FUNDING$6B valuation

General Intuition Hits $6B Valuation on Robotics Push

Valor Equity Partners and Point72 are backing General Intuition at a $6 billion valuation as the spatial-reasoning AI startup extends from video-game agents into physical robotics.

FUNDING· Aug 24, 2026

Unicorns Are Buying Startups at Record Pace

Illustration for: Unicorns Are Buying Startups at Record Pace
FUNDING

Unicorns Are Buying Startups at Record Pace

Ultra-high-valuation private companies are driving a wave of startup-on-startup acquisitions across AI, fintech and biotech, using their own paper as currency.

FUNDING· Aug 24, 2026

Zcash Hits Eight-Year High on ETF Hopes

Illustration for: Zcash Hits Eight-Year High on ETF Hopes
FUNDING

Zcash Hits Eight-Year High on ETF Hopes

Zcash has climbed to its highest level in eight years amid a broader crypto rally and expectations that a spot ETF could be approved.

Deep Dives

$1.63B Raised, 36% Faster — Health Insurance AI (2026)AI Tutor Education Startups 2026: Duolingo's $1.2B, Khanm...Fund I vs Fund II VC Performance: Does the Sophomore Fund...
@Trace_Cohen·t@nyvp.com